Moomoo AI 已提取核心信息
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in financial performance for the period from January 1, 2023, to December 31, 2023. The company's sales surged by 31% in Danish kroner and 36% at constant exchange rates (CER), reaching DKK 232.3 billion. The operating profit followed suit, with a 37% increase in Danish kroner and a 44% rise at CER, amounting to DKK 102.6 billion. North America Operations saw a remarkable 50% growth in sales, while International Operations experienced an 11% increase. The Diabetes and Obesity care segment was a major contributor to this growth, with sales rising by 38% to DKK 215.1 billion, driven by GLP-1 diabetes sales and a staggering 147% increase in Obesity care sales. However, Rare disease sales saw a decrease of 16%. Novo Nordisk also...Show More
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in financial performance for the period from January 1, 2023, to December 31, 2023. The company's sales surged by 31% in Danish kroner and 36% at constant exchange rates (CER), reaching DKK 232.3 billion. The operating profit followed suit, with a 37% increase in Danish kroner and a 44% rise at CER, amounting to DKK 102.6 billion. North America Operations saw a remarkable 50% growth in sales, while International Operations experienced an 11% increase. The Diabetes and Obesity care segment was a major contributor to this growth, with sales rising by 38% to DKK 215.1 billion, driven by GLP-1 diabetes sales and a staggering 147% increase in Obesity care sales. However, Rare disease sales saw a decrease of 16%. Novo Nordisk also completed significant clinical trials, including the first phase 3a trial with IcoSema and a phase 1 trial with oral amycretin. Looking ahead to 2024, the company anticipates sales growth of 18-26% at CER and operating profit growth of 21-29% at CER. The Board of Directors plans to propose a final dividend of DKK 6.40 per share for 2023 at the Annual General Meeting on March 21, 2024, and has initiated a new share repurchase programme of up to DKK 20 billion.
全球领先的医疗保健公司诺和诺德A/S报告称，从2023年1月1日至2023年12月31日期间，财务业绩大幅增长。该公司的销售额以丹麦克朗计算增长了31％，按固定汇率（CER）计算增长了36％，达到2323亿丹麦克朗。营业利润紧随其后，丹麦克朗增长了37％，按CER计算增长了44％，达到1,026亿丹麦克朗。北美业务的销售额显著增长了50％，而国际业务的销售额增长了11％。糖尿病和肥胖症护理板块是这一增长的主要推动力，销售额增长了38％，达到2151亿丹麦克朗，这得益于 GLP-1 糖尿病销售额和肥胖护理销售额惊人的147％增长。但是，罕见病的销售额下降了16％。诺和诺德还完成了重要的临床试验，...展开全部
全球领先的医疗保健公司诺和诺德A/S报告称，从2023年1月1日至2023年12月31日期间，财务业绩大幅增长。该公司的销售额以丹麦克朗计算增长了31％，按固定汇率（CER）计算增长了36％，达到2323亿丹麦克朗。营业利润紧随其后，丹麦克朗增长了37％，按CER计算增长了44％，达到1,026亿丹麦克朗。北美业务的销售额显著增长了50％，而国际业务的销售额增长了11％。糖尿病和肥胖症护理板块是这一增长的主要推动力，销售额增长了38％，达到2151亿丹麦克朗，这得益于 GLP-1 糖尿病销售额和肥胖护理销售额惊人的147％增长。但是，罕见病的销售额下降了16％。诺和诺德还完成了重要的临床试验，包括第一项针对icoSema的3a期试验和一项口服阿米克雷汀的1期试验。展望2024年，该公司预计，按CER计算，销售额将增长18-26％，按CER计算，营业利润将增长21-29％。董事会计划在2024年3月21日的年度股东大会上提出2023年每股6.40丹麦克朗的末期股息，并启动了一项高达200亿丹麦克朗的新股票回购计划。
有用
没用